← Leaderboards
Steven H Bernstein
Roswell Park Cancer Institute Corp
$2,820,683
Attributed
$2,820,683
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2008–12$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,120,007 · 4
By mechanism
P50$3,377,849 · 2
R01$1,583,991 · 1
R21$158,167 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Renier Joseph Brentjens$12,958,252
- Martin L Brecher$381,449
Others in their field
Top investigators on “Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
LymphomaLeadCellsIn VitroBaseRefractoryPublishingTumorIn VivoMediatingCell DeathProteinsRelapseAftercareResearch PersonnelProteasome InhibitorLymphocyteMalignant Lymphoma, Lymphocytic, Intermediate Differentiation, DiffuseClinical TrialsDesignCancer CenterDiffuseOxidation-ReductionTumor Antigens
Grant awards (12)
SPORE in Lymphoma$2,299,324
P50 · FY2012 · CA · contact PI
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients$308,376
R01 · FY2012 · CA · contact PI
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL$220,488
P50 · FY2012 · CA · contact PI
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients$308,376
R01 · FY2011 · CA · contact PI
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL$208,731
P50 · FY2011 · CA · contact PI
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients$317,913
R01 · FY2010 · CA · contact PI
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL$219,543
P50 · FY2010 · CA · contact PI
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients$319,918
R01 · FY2009 · CA · contact PI
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL$257,420
P50 · FY2009 · CA · contact PI
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients$329,408
R01 · FY2008 · CA · contact PI
P- 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL$172,343
P50 · FY2008 · CA · contact PI
VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA$158,167
R21 · FY2000 · CA